PepperLedger
COMPOUND LIBRARY·IPAMORELIN
COMPOUND PROFILE · PEPPERLEDGER

Ipamorelin

Type
Synthetic pentapeptide — ghrelin receptor agonist (GH secretagogue)
Class
GHSR agonist — stimulates pituitary to release endogenous GH via ghrelin receptor pathway
Administration
Subcutaneous injection
Half-life
~2 hours (pulsatile release)
Most studied use
GH stimulation for recovery, sleep, and body recomposition · Often stacked with CJC-1295
Regulatory status
Not FDA-approved for performance enhancement · Phase II data for post-surgical GI indication · Research chemical in U.S.
Human evidence
PK/PD study in volunteers + Phase II for post-surgical ileus · No RCTs for body composition
Preclinical evidence
Strong — multiple rodent studies confirming GH potency, bone effects, selectivity

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor (GHSR) in your pituitary gland, triggering release of your own endogenous growth hormone. It's not GH itself — it's a signal that tells your pituitary to produce more of your own. What distinguishes ipamorelin from other GH secretagogues is selectivity: it activates the GH-releasing pathway without significantly touching the other pathways that ghrelin activates, like appetite stimulation or cortisol elevation.

That selectivity is the core reason ipamorelin has become the default starting point for biohackers entering the GH secretagogue space. MK-677 (another popular ghrelin mimetic) activates ghrelin pathways broadly — which means more appetite, more water retention, and higher cortisol alongside the GH elevation. Ipamorelin delivers similar GH-releasing potency with a dramatically cleaner side-effect profile. The trade-off is that it requires injection and has a short half-life (~2 hours), so it's typically dosed 1–3 times daily.

GH declines naturally with age — roughly 10–15% per decade from your 30s onward. This decline corresponds with the loss of muscle, increase in body fat, slower recovery, and reduced sleep quality that most people associate with aging. Ipamorelin's appeal is the ability to restore GH signaling without the receptor-desensitization risks of direct GH injection, without the appetite and cortisol issues of less selective secretagogues, and without suppressing endogenous GH production.

Most biohackers run ipamorelin stacked with CJC-1295 (without DAC) — combining two different receptor pathways for synergistic GH elevation. The honest evidence picture: ipamorelin has solid animal data confirming GH-releasing potency and anabolic effects. Human pharmacokinetic data confirms the mechanism works in people. But there are no randomized controlled trials in healthy adults testing body composition, recovery, or anti-aging outcomes. The mechanism is sound; the clinical validation for those specific outcomes is extrapolated from mechanism and animal data.

How it works

Ghrelin Receptor Activation and GH Release

Ipamorelin binds selectively to the ghrelin receptor (GHSR/GHS-R1a) on somatotroph cells in the anterior pituitary. This activates G-alpha-11 coupled signaling, increasing intracellular cAMP and PKA activity, which directly stimulates GH gene transcription and pulsatile GH secretion. The GH released then travels to the liver to stimulate IGF-1 production — the primary downstream mediator of GH's anabolic effects.

Why Selectivity Matters

Ghrelin itself activates multiple pathways: GH release, appetite stimulation via hypothalamic neuropeptide Y neurons, gastric motility, and cortisol/ACTH release. Ipamorelin is engineered to favor GH-releasing receptor binding without strongly activating these secondary pathways. In preclinical studies, ipamorelin showed GH-releasing potency comparable to GHRP-6 but without the significant cortisol or prolactin elevations GHRP-6 produces. This selectivity profile — high GH potency, low cortisol — is the core pharmacological achievement.

Pulsatile GH — Why It's Better Than Continuous

Ipamorelin produces pulsatile GH release — brief spikes that clear within 2 hours, matching your body's natural rhythm. Pulsatile GH preserves GHRH receptor sensitivity and avoids the negative feedback that continuous GH elevation triggers. Endogenous GH production continues between doses — you're amplifying a natural signal, not replacing it.

The CJC-1295 + Ipamorelin Stack

CJC-1295 (no-DAC)acts on GHRH receptors; ipamorelin acts on ghrelin receptors. These are different receptor systems that both converge on GH release through different intracellular pathways. Combining them produces synergistic GH elevation — meaningfully greater than either alone — because you're stimulating two independent release mechanisms simultaneously. This is why the stack has become the standard in biohacker GH-optimization protocols.

What the research shows

HUMAN EVIDENCE
STUDYEuropean Journal of Endocrinology · 1998

Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers

Raun K, Hansen BS, Johansen NL et al.

First human PK/PD study. Confirmed dose-dependent GH-releasing potency in healthy volunteers. Established the ~2-hour half-life pharmacokinetic profile and confirmed selectivity — minimal cortisol or prolactin elevation at effective GH-releasing doses.

View on PubMed →
STUDYGut · 2015

Prospective, randomized, controlled proof-of-concept study of ipamorelin for postoperative ileus

Camilleri M et al.

Phase II trial in post-surgical patients — focused on gastric motility, not body composition. Confirmed safety and tolerability profile in a human clinical setting. Establishes human safety data beyond the initial PK study.

View on PubMed →
PRECLINICAL — KEY STUDIES
STUDYEuropean Journal of Endocrinology · 1998

Ipamorelin, the first selective growth hormone secretagogue

Raun K et al.

Established ipamorelin's selectivity profile in vitro and in vivo. EC₅₀ ≈ 1.3 nmol/L — high GH-releasing potency comparable to GHRP-6 but without significant cortisol, prolactin, or ACTH elevation. The foundational selectivity study.

View on PubMed →
STUDYGrowth Hormone & IGF Research · 1999

Ipamorelin induces longitudinal bone growth in rats

Raun K et al.

Dose-dependent increases in bone growth rate (42→52 μm/day). Demonstrates anabolic skeletal effects — supporting the mechanistic case for ipamorelin's role in bone density and connective tissue health.

View on PubMed →
STUDYGrowth Hormone & IGF Research · 2000

Ipamorelin and GHRP-6 increase bone mineral content in aged female rats

Raun K et al.

Bone mineral content increased in aging rats. Supports anti-aging and bone health claims. Also notable for confirming the selectivity advantage over GHRP-6 in terms of cortisol.

View on PubMed →
WHAT THE RESEARCH SHOWS
KNOWN
  • Selective for GHSR — minimal cortisol, prolactin, or appetite effects
  • ~2-hour half-life, pulsatile GH release profile
  • GH-releasing potency confirmed in human volunteers
  • Anabolic skeletal effects in animal models
  • Safety and tolerability in human clinical setting (GI trial)
?UNCERTAIN
  • ?Long-term human safety beyond 6 months
  • ?Optimal human dosing for body composition outcomes
  • ?Whether CJC-1295 + ipamorelin stack has superior outcomes vs. either alone (no head-to-head trial)
  • ?Body composition and recovery outcomes in healthy adults (no RCTs)
  • ?Tolerance or desensitization with long-term daily use

What the community reports

Ipamorelin — particularly stacked with CJC-1295 — has one of the most documented anecdotal track records in the biohacker GH-optimization space. The consistency of reports across years and diverse user backgrounds is worth taking seriously as practical evidence, especially for the sleep and recovery signals which appear in virtually every long-term account.

Better sleep quality — consistently the earliest and most reliable effect; deeper sleep, fewer wakings, more vivid dreams; often noticeable within 1–2 weeks
Faster post-workout recovery — reduced DOMS, ability to train at higher frequency; reported across athletic and non-athletic users
Gradual fat loss, particularly around the midsection — typically appearing by weeks 4–8 with consistent nutrition; described as steady rather than dramatic
Improved muscle definition and gradually increasing lean mass — most users report 5–10 lbs lean mass over 3–6 months with consistent resistance training
Stable energy and improved mood — distinctly described as clean rather than stimulant-like; no crash, no jitter
Minimal appetite increase compared to MK-677 — one of the most commonly cited reasons for preferring ipamorelin
No meaningful cortisol elevation — users who have also run GHRP-6 consistently note ipamorelin as meaningfully cleaner

The sleep signal in ipamorelin reports deserves particular attention. It appears in accounts from users across age groups, body types, training styles, and dosing schedules. That consistency — showing up reliably regardless of other protocol variables — aligns precisely with the mechanistic story: GH secretion peaks during slow-wave sleep, and stimulating GH release at night amplifies the natural sleep-GH relationship. When community experience and mechanism align this consistently, it's a meaningful signal.

Biology is individual. Age, baseline GH levels, sleep quality, diet, and training consistency all influence how much you'll notice. Track your sleep quality, recovery metrics, and energy levels specifically in the first two weeks — these are the clearest early indicators of whether the compound is working for your specific biology.

Common misconceptions

"Ipamorelin is just like taking growth hormone."

REALITY

Ipamorelin stimulates your own pituitary to release GH in a pulsatile pattern. Direct GH injection creates a flat, continuous elevation that suppresses your natural production and bypasses your feedback loops. Ipamorelin preserves natural GH rhythms and endogenous production — mechanistically superior for long-term use.

"Ipamorelin will make you hungry and bloated like MK-677."

REALITY

This is the key differentiator. MK-677 activates all ghrelin pathways including appetite and gastric motility. Ipamorelin is selective for the GH-releasing pathway with minimal activation of appetite-stimulating effects. Water retention and appetite increase are much milder than MK-677 — many users report none at all.

"Results are guaranteed if you use ipamorelin correctly."

REALITY

Ipamorelin amplifies what you're already doing. Results depend heavily on diet, training, sleep, age, and baseline GH levels. Someone with excellent sleep, consistent resistance training, and dialed-in nutrition will see substantially more from ipamorelin than someone who isn't training. It's a multiplier, not a shortcut.

"Daily dosing is necessary for results."

REALITY

Most users dose 1–3 times daily, but some find meaningful results with once-daily pre-sleep dosing to amplify the natural GH peak during slow-wave sleep. Frequency depends on your goals — before-bed dosing maximizes sleep and recovery benefit; additional daytime doses may add body composition benefits at the cost of more injections.

"Ipamorelin alone is as effective as the CJC-1295 + ipamorelin stack."

REALITY

Ipamorelin alone produces GH elevation through the ghrelin receptor pathway. CJC-1295 (no-DAC) works through the GHRH receptor pathway — a different mechanism. The combination produces synergistic GH elevation greater than either alone. Most experienced biohackers consider the stack meaningfully superior for body composition goals.

RECONSTITUTION CALCULATOR

EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN

AI COACH PREVIEW
I'm starting ipamorelin + CJC-1295. Should I dose before bed only or split morning and evening?
The before-bed approach is the right starting point for most people. Here's the logic: GH naturally peaks during slow-wave sleep in the first few hours after you fall asleep. Dosing ipamorelin + CJC-1295 (no-DAC) 30–45 minutes before bed amplifies that natural peak — which is why the sleep improvement is usually the first thing users notice. You're working with your body's existing GH rhythm rather than creating a second separate pulse. For body composition goals, the before-bed approach captures both the sleep benefit and the overnight anabolic window, which is when much of your muscle protein synthesis and fat oxidation happens anyway. The case for adding a morning or pre-workout dose: if your primary goal is intra-workout recovery and you want maximum daytime GH elevation for training performance, a pre-workout dose (empty stomach, 30–60 min before training) adds another pulse through the day. This matters more for people with high training volumes. My suggestion for your first 4 weeks: start with before-bed only, track your sleep quality and morning energy. If you're noticing clear benefit and want to push body composition harder, add a pre-workout dose then. Starting with one dose lets you isolate the compound's effects cleanly.
CONTINUE IN THE APP

Open PepperLedger to build your ipamorelin + CJC-1295 stack →

Free to join. No credit card. Ask the Coach about timing and dosing for your specific goals.

Free to join · No credit card · 23-day Pro trial included

PepperLedger

Educational tool — not medical advice. PepperLedger is a logging and information tool for adults managing their own protocols. It does not prescribe, diagnose, or treat anything. Always work with a qualified healthcare provider for medical decisions.

© 2026 Realee AI · PepperLedger